Digitalis
drugOn this page
Also known as DigifortisDigiglusinDigitalis leafDigitalis leavesDigitalis purpureaDigitalis purpurea leafDigitalis purpurea leaf extractDigitalis purpurea wholepowderedFoxglove leafFoxglove wholeMao di huang leafMao di huang wholePurple foxglove leafPurple foxglove whole
Summary
Digitalis (CHEMBL2109172) is a phase-3 clinical-stage unknown (ATC C01AA03); indicated across 4 conditions including cardiovascular disorder and congestive heart failure.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- ATC class: C01AA03
- Indications: 4 conditions
- Clinical trials: 1
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2109172 |
| Name | Digitalis |
| Type | Unknown |
| Max phase | 3 |
| ATC | C01AA03 |
Also known as: Digifortis, Digiglusin, Digitalis, Digitalis leaf, Digitalis leaves, Digitalis purpurea, Digitalis purpurea leaf, Digitalis purpurea leaf extract, Digitalis purpurea whole, powdered, Foxglove leaf, Foxglove whole
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| cardiovascular disorder | 3 | MONDO:0004995 | EFO:0000319 |
| congestive heart failure | 3 | MONDO:0005009 | EFO:0000373 |
| heart failure | 3 | MONDO:0005252 | EFO:0003144 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 1.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00000476 | PHASE3 | COMPLETED | Digitalis Investigation Group (DIG) |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).